| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $6.7M | — | +82.3% |
| SG&A Expense | $1.6M | — | +10.2% |
| Operating Income | -$8.3M | — | -61.5% |
| Net Income | -$8.2M | — | -41.3% |
| EPS (Basic) | -$4.35 | — | -1877.3% |
| EPS (Diluted) | -$4.35 | — | -1877.3% |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.7M | -74.1% | -53.1% |
| Short-term Investments | $7.5M | +1.2% | — |
| Current Assets | $11.3M | -43.0% | +38.1% |
| Total Assets | $13.1M | -39.6% | +25.5% |
| Current Liabilities | $3.3M | -16.6% | -33.5% |
| Stockholders' Equity | $9.4M |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$7.7M | — | -10.8% |
| Investing Cash Flow | -$75K | — | +0.0% |
| Financing Cash Flow | $12.0M | — | +0.0% |
| +151.8% |